SCHEMBL9258652

SCHEMBL9258652

Cc1csc(-c2cccc(C(F)(F)F)c2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
KDM4E B2RXH2 1/20 0.52
TLR7 Q9NYK1 1/20 0.51
CYP2E1 P05181 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2A6 P11509 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2B6 P20813 1/20 0.50
PIM1 P11309 1/20 0.48
MAPT P10636 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
GRM5 P41594 1/20 0.45
MAPK1 P28482 2/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
IKBKB O14920 1/20 0.43
BRD4 O60885 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28743338 0.83 ALDH1A1 (0.71) ALDH1A1MEN1KMT2AKDM4ETLR7
SCHEMBL9258647 0.81 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL9831167 0.81 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL2307283 0.80 CYP2E1 (0.47) SMN1; SMN2MEN1KMT2AKDM4ETLR7
SCHEMBL21479644 0.79 KMT2A (0.67) ALDH1A1MEN1KMT2AKDM4ETLR7
SCHEMBL30279814 0.79 KMT2A (0.67) ALDH1A1MEN1KMT2AKDM4ETLR7
SCHEMBL5547117 0.79 KDM4E (0.56) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL12266908 0.78 CYP2E1 (0.57) ALDH1A1MEN1KMT2ACYP2E1CYP3A4
SCHEMBL1198258 0.78 KDM4E (0.58) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL16399190 0.78 PIM1 (0.60) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3822253-A1 METHOD FOR PREPARING PROPANEDINITRILE OXIME ETHER COMPOUND AND INTERMEDIATE COMPOUND Shenyang Sinochem Agrochemicals R&D Co., Ltd. (CN) 2021-05-19 EP disclosed
US-7960398-B2 Potent inhibitors of TNF activity VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-14 US disclosed
US-7807659-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-05 US disclosed
US-7807659-B2 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-05 US disclosed
US-7410956-B2 Caspase inhibitor prodrugs VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-08-12 US disclosed
US-20070010457-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2007-01-11 US disclosed
US-20070010457-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2007-01-11 US disclosed
US-5395845-A Insecticides ROUSSEL-UCLAF (FR) 1995-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010457-A1 Caspase inhibitors and uses thereof CASP1, APAF1, TNF ALDH1A1 1646/4885SMN1; SMN2 3615/4885MEN1 2412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.